Scemblix Demonstrates Major Molecular Response Improvements in Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Phase 3 trial results showed that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.